Session 139 - 12th CROI

Home

Session 139 Poster Abstracts
Impact of Antiretroviral Therapy during Pregnancy
Friday, 1:30 - 3:30 pm
Hall B

806	Receipt of PI-containing HAART during Pregnancy and Adverse Pregancy Outcomes (Low Birth Weight, Preterm Birth) among HIV-1-infected Women in Latin America and the Caribbean: The NICHD International Site Development Initiative Perinatal Study E Szyld¹, R Gonin², Eduardo Warley*¹, P Cahn³, G Calvet⁴, G Duarte⁵, V Melo^6,12, J Korelitz², E Cardoso⁷, A Duran⁸, L Freimanis², R Succi⁹, R de Souza¹⁰, D Chang², and J Read¹¹ ¹Hosp Diego Paroissien, Buenos Aires, Argentina; ²Westat, Rockville, MD, USA; ³Hosp J A Fernandez, Buenos Aires, Argentina; ⁴Hosp dos Servidores do Estado, Rio de Janeiro, Brazil; ⁵Univ of Sao Paulo Sch of Med, Ribeirao Preto, Brazil; ⁶Fed Univ of Minas Gerais Sch of Med, Belo Horizonte, Brazil; ⁷Hosp Conceição, Porto Alegre, Brazil; ⁸Hosp Gen de Agudos Jose Maria Ramos Mejia, Buenos Aires, Argentina; ⁹Federal Univ of Sao Paulo, Brazil; ¹⁰STD/HIV Clin, Caxias do Sul, Brazil; ¹¹NICHD, NIH, DHHS, Bethesda, MD, USA; and ¹²Maternidade Odete Valadares, Belo Horizonte, Brazil
807	97% Progression-free Survival of HIV+ Pregnant Women 33 Months Post-delivery Fabiola Martin*¹, L Navaratne², W Khan³, L Sarner⁴, D Mercey⁵, J Anderson⁶, H Noble⁴, A Fakoya⁴, D Hawkins³, A de Ruiter², G Taylor¹, and The London HIV Perinatal Research Group ¹St Mary's Hosp, London, UK; ²St Thomas' Hosp, London, UK; ³Chelsea and Westminster Hosp, London, UK; ⁴Newham Hlthcare NHS Trust, London, UK; ⁵Mortimer Market Ctr, London, UK; and ⁶Homerton Univ NHS Trust, London, UK
808	Pregnancy Outcome in HIV-1-infected Women Receiving Combination Therapy Prior to Conception Elizabeth Machado*¹, C Hofer¹, S Nogueira^2,3, T Costa⁴, and J Lambert⁵ ¹Univ Hosp Clementino Fraga Son, Federal Univ of Rio de Janeiro, Brazil; ²Univ Hosp Clementino Fraga Son, Federal Univ of Rio de Janeiro, Brazil; ³Federal Univ of Rio de Janeiro, Brazil; ⁴Federal Univ of Rio de Janeiro, Brazil; and ⁵Inst of Human Virology, Univ of Maryland, Baltimore, USA
809	Preliminary Findings: Incidence of Serious Adverse Events Attributed to Nevirapine among Women Enrolled in an Ongoing Trial Using HAART tor Prevent Mother-to-Child HIV Transmission Timothy Thomas*¹, P Amornkul¹, J Mwidau^1,2, R Masaba¹, L Slutsker¹, D Mwaengo¹, J Vulule¹, K DeCock¹, and M Fowler³ ¹Kenya Med Res Inst/CDC, Kisumu; ²Univ of Miami, FL, USA; and ³CDC, Atlanta, GA, USA
810	ARTwith Indinavir –Ritonavir (400 mg/100 mg Twice Daily)-containing Regimen in HIV-1-infected Pregnant Women Roland Tubiana*¹, S Dominguez¹, C Perot¹, C Cornelie¹, A Marcelin¹, M Pauchard¹, Z Ouagari¹, J Ghosn¹, G Peytavin², I De Montgolfier¹, R Agher¹, V Calvez¹, F Bricaire¹, M Dommergues¹, and C Katlama¹ ¹Hosp Pitie-Salpetriere, Paris, France and ²Hosp Bichat-Claude Bernard, Paris, France